Intact Investment Management Inc. Acquires Shares of 500 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Intact Investment Management Inc. purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 500 shares of the biopharmaceutical company's stock, valued at approximately $356,000.

A number of other institutional investors have also recently modified their holdings of the business. State Street Corp boosted its stake in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock valued at $5,153,603,000 after buying an additional 61,277 shares in the last quarter. Amundi raised its holdings in shares of Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after acquiring an additional 487,489 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company's stock worth $495,639,000 after acquiring an additional 22,538 shares during the last quarter. Swiss National Bank raised its holdings in shares of Regeneron Pharmaceuticals by 0.6% in the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company's stock worth $338,079,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company's stock valued at $215,562,000 after purchasing an additional 1,108 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on REGN shares. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research report on Tuesday, February 4th. Truist Financial cut their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. Finally, Robert W. Baird cut their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $9.74 on Thursday, reaching $662.62. 662,935 shares of the stock traded hands, compared to its average volume of 627,888. The firm's fifty day simple moving average is $691.62 and its 200 day simple moving average is $822.93. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market cap of $72.44 billion, a price-to-earnings ratio of 17.31, a P/E/G ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company posted $11.86 EPS. The firm's quarterly revenue was up 10.3% on a year-over-year basis. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.